Sales of Zecuity Migraine Skin Patches Halted

Share this content:
Sales of Zecuity Migraine Skin Patches Halted
Sales of Zecuity Migraine Skin Patches Halted

TUESDAY, June 14, 2016 (HealthDay News) -- Sales of the migraine treatment skin patch Zecuity (sumatriptan iontophoretic transdermal system) have been halted after patients reported suffering burns and scars where the patches were applied, Teva Pharmaceutical says.

The Israel-based company also said consumers with the disposable battery-powered patches should stop using them, the Associated Press reported.

The patch is designed to deliver a dose of medicine via a single-use, battery-powered patch that is wrapped around the upper arm or thigh. But some users have developed severe redness, skin discoloration, cracked skin, and pain where patches were applied, according to the U.S. Food and Drug Administration.

Teva said it is recalling the patches and working with the FDA to determine the cause of the skin reactions, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Attempted Suicide Rates, Risk Groups Mostly Unchanged

Attempted Suicide Rates, Risk Groups Mostly Unchanged

Men more often resort to violent means, while women turn to poisoning, drowning

New Visual Symptoms Not Uncommon After LASIK Surgery

New Visual Symptoms Not Uncommon After LASIK Surgery

But most patients report satisfaction with the procedure

Many With Postconcussion Syndrome Don't Recover

Many With Postconcussion Syndrome Don't Recover

Only 27 percent of population recovered; 67 percent of those who recovered did so in first year

is free, fast, and customized just for you!

Already a member?

Sign In Now »